Sentences with phrase «with median survival»

Prognosis — Conventional chemotherapy results in total remission in approximately 60 - 90 % of cases with a median survival time of 6 - 12 months.

With chemotherapy treatments, total remission is approximately 60 - 90 % of cases with a median survival time of 6 - 12 months.

In another study, cats that presented in heart failure lived a median of 77 days whereas those without heart failure fared much better, with a median survival of 223 days.

The incidence of MDS in children is very low, however, after chemotherapy or radiation, as many as 2 - 6 % will develop MDS, with a median survival of only 13 months!

The therapy has greatly helped the majority of the patients, most of whom had undergone heavy treatments before and had prognoses with a median survival time (without the TAT therapy) of 2 - 4 months.

Glioblastoma multiforme is the most common and aggressive form of brain cancer, with a median survival of about 15 months.

The infection is virtually always fatal, with a median survival time after the onset of symptoms of four days.

Patients have a very poor prognosis, with median survival of just 14 to 16 months.

Not exact matches

Without resection, overall median survival is four to six months with an estimated five - year survival rate of 0.4 percent to 5 percent.

Brahmer emphasizes that the relatively small increase in median survival time with the use of the new immunotherapy drugs may be somewhat misleading in terms of overall impact of the medicines.

Median overall survival of patients receiving nivolumab was 9.2 months, compared with six months for patients who received docetaxel.

While there have been improvements in the current standard treatments, patients with glioblastoma (GBM), the most common and aggressive form of brain tumor, still suffer from a median survival rate of only 14.6 months and 5 - year overall survival rates of less than 10 %.

Of the dogs stricken with osteosarcoma, 35 had the cancer in a leg which was subsequently amputated, followed by chemotherapy, which is the standard - of - care treatment; the dogs with elevated total cholesterol had a median survival time of 455 days, more than 200 days greater than the median survival time for dogs with normal cholesterol.

Patients treated with precision medicine also benefited from longer progression - free survival with a median of 5.7 months before their disease worsened compared to 2.95 months for the others.

The median survival for patients is 15 months, with less than five per cent of patients surviving beyond five years.

Median progression - free survival for the 13 patients who had a decrease in the number of CTCs with ALK copy number gain was 14.0 months, while the median progression - free survival for the 16 patients who had stable or increased numbers of CTCs with ALK copy number gain was 6.1 mMedian progression - free survival for the 13 patients who had a decrease in the number of CTCs with ALK copy number gain was 14.0 months, while the median progression - free survival for the 16 patients who had stable or increased numbers of CTCs with ALK copy number gain was 6.1 mmedian progression - free survival for the 16 patients who had stable or increased numbers of CTCs with ALK copy number gain was 6.1 months.

With standard treatments of surgery, chemotherapy and radiation, the median survival time is only 14.6 months, and improvement will only come with the ability to kill tumor cells resistant to standard treatments, according to Alfredo Quiñones - Hinojosa, M.D., a professor of neurosurgery at the Johns Hopkins University School of Medicine and a member of the research tWith standard treatments of surgery, chemotherapy and radiation, the median survival time is only 14.6 months, and improvement will only come with the ability to kill tumor cells resistant to standard treatments, according to Alfredo Quiñones - Hinojosa, M.D., a professor of neurosurgery at the Johns Hopkins University School of Medicine and a member of the research twith the ability to kill tumor cells resistant to standard treatments, according to Alfredo Quiñones - Hinojosa, M.D., a professor of neurosurgery at the Johns Hopkins University School of Medicine and a member of the research team.

As reported in 2015, the study met its primary endpoint after a median follow up of 2.3 years, with ipilimumab significantly improving recurrence - free survival.2 The drug was subsequently approved by the US Food and Drug Administration as adjuvant therapy for stage III melanoma.

The median survival rate for patients with metastatic uveal melanoma is 12 months.

Median overall survival for patients on selumetinib was 11.8 months, compared with 9.1 months for those on chemotherapy, but the difference was not statistically significant.

The interim analysis found a median progression - free survival rate of 9.7 months with consolidative radiation therapy followed by chemotherapy, versus 3.5 months for maintenance chemotherapy alone (p = 0.01; Hazard Ratio (HR) = 0.304, 95 % CI 0.113 - 0.815).

However, median progression - free survival is statistically significant, with the control group at about 8.6 months and the treatment group at 24.5 months — a 16 - month advantage for the ICT - 107 group.

In patients with HLA - A2 and methylated MGMT, neither the control group nor the treatment group has reached a median survival point to date.

Study results show that patients with prior knowledge of MGUS had better overall survival (median 2.8 years) than patients with MM who didn't know when they had MGUS (median survival 2.1 years), although patients with prior knowledge of their MGUS status had more coexisting illnesses.

Median progression - free survival was significantly improved with ceritinib compared to chemotherapy (5.4 vs 1.6 months, hazard ratio [HR] 0.49, p < 0.001).

More than half of those with abundant F.prausnitzii had not reached median progression - free survival, while half of those with low abundance had their disease progress by 242 days.

As of April 2015, with a median follow up of 30.1 months, the media progression free survival was 19.1 months and the median overall survival had increased to 32.1 months.

The team found that patients with more varied types of bacteria in their digestive tract had longer median progression - free survival, defined at the time point where half of studied patients have their disease progress.

The researchers then tested their scoring method using data on 688 AML patients in three different clinical trials, In each of these groups, patients with low scores (methylation patterns similar to normal HSCs) had approximately twice the median survival time of patients with high scores.

Appearing in Lancet Oncology, long term results of EORTC trial 22921 with 10.4 years median follow - up show that 5 - FU (fluorouracil) based adjuvant chemotherapy after preoperative (chemo)- radiotherapy for patients with cT3 - resectable T4 M0 rectal cancer does not improve survival or disease - free survival.

Median overall survival for woman in the chemotherapy plus bevacizumab treatment was 42.2 months, compared with 37.3 for those receiving chemotherapy alone.

The researchers found that patients capable of holding their breath over the course of treatment had a 90 percent disease - free survival, and a 96 percent overall survival, with a median reduction in radiation dose to the heart of 62 percent.

The median survival rate for patients with glioblastoma multiforme, or GBM, is a mere 14.2 months.

For example, data from seven multi-institutional U.S. clinical trials showed patients who had no visual residual disease had a median survival of 64 months compared with 29 months for those with minimal residual cancer.

Mean progression - free survival was 3.1 months with regorafenib and 1.5 months with placebo, while median overall survival was 10.6 months for regorafenib and 7.8 months with placebo.

Median progression - free survival with niraparib compared to placebo was 21.0 vs 5.5 months in the germline BRCA mutation group (hazard ratio [HR] 0.27, 95 % confidence interval [CI] 0.173 to 0.410, p < 0.0001), 9.3 months vs 3.9 months in the non-germline BRCA mutation group (HR 0.45, 95 % CI 0.338 to 0.607, p < 0.0001), and 12.9 vs 3.8 months in a subgroup of the non-mutation cohort who had homologous recombination DNA repair deficiencies (HRD)(HR 0.38, 95 % CI 0.243 to 0.586, p < 0.0001).

«While the median survival rate for patients without distant metastasis was nearly a year - and - a-half with this treatment, there was one patient whose disease remained clinically stable for nearly three years.

With a median follow - up of 36.7 months, the researchers found no survival benefit of chemoradiotherapy compared with chemotherapy, with median overall survival from the date of the first randomization of 15.2 months and 16.5 months, respectivWith a median follow - up of 36.7 months, the researchers found no survival benefit of chemoradiotherapy compared with chemotherapy, with median overall survival from the date of the first randomization of 15.2 months and 16.5 months, respectivwith chemotherapy, with median overall survival from the date of the first randomization of 15.2 months and 16.5 months, respectivwith median overall survival from the date of the first randomization of 15.2 months and 16.5 months, respectively.

The median disease - free survival was 13.4 months in the treatment group compared with 6.7 months in the observation group.

The researchers found a statistically significant difference in overall survival between the study groups, with a median of 22.8 months in the gemcitabine group compared with 20.2 months in the observation group.

At five years, 34 of the 102 patients had achieved a complete response (disappearance of their cancer for a period of time), with an estimated 64 percent of patients surviving with or without disease (median five - year overall survival was 40.5 months) and an estimated 52 percent surviving without disease progression.

In Canada, one in every 3,600 children are diagnosed with CF.. But life expectancy rates have risen dramatically in recent decades with the median age of survival now over 50 years, due to better treatments to improve lung function, better nutrition and lung transplants.

At five years, the rates for disease - free and overall survival were 26 percent and 40 percent, respectively, with a median overall survival of four years.

Among 128 of the 141 patients, the scientists found that the median progression - free survival of 71 patients identified with high levels of cancer DNA in their blood was 2.1 months, compared with 5.8 months for 57 patients with low levels.

Women with Stage III ovarian cancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone, according to a study published conducted by the Gynecologic Oncology Group (GOG), a National Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of Medicine.

Sweeney said more time is needed to assess the benefit of the drug combination in the men with lesser burdens of disease, as their median survival has not yet been reached.

The tumors grew rapidly in the control experiments (the median time for tumor - free survival was one week) and any differences in tumor - free survival for the controls and the mice injected with cells expressing mutated PREX2 were not statistically significant (Horrigan et al., 2017).

In the 520 patients who had high - extent disease (whose cancer had spread to major organs and / or the bones), treatment with ADT plus docetaxel had an even greater benefit: these men had a median overall survival of 49.2 months versus 32.2 in the ADT - only group — a difference of 17 months.

A class of oral specialty drugs, tyrosine kinase inhibitors (TKIs), has revolutionized the treatment of CML, largely transforming it into a chronic condition and enabling many patients to have a near - normal lifespan, particularly when compared to a median survival of less than three years with prior therapies.

This translated into a median overall survival of 57.6 months for men who received early chemotherapy compared with 44 months in the group given ADT as the only initial treatment — more than a year of additional life.